Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.19.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 125,574 $ 48,995
Marketable securities 139,182 129,669
Accrued interest receivable 481 304
Prepaid expenses 4,827 2,594
Total current assets 270,064 181,562
Property and equipment, net 2,794 2,905
Operating lease right-of-use asset 177  
Other assets 1,122 2,280
Total assets 274,157 186,747
Current liabilities:    
Accounts payable 2,410 1,973
Accrued clinical trial expenses 9,281 8,588
Other accrued liabilities 2,782 3,854
Total current liabilities 14,473 14,415
Long-term portion of operating lease liability 2,053  
Other liabilities   1,914
Total liabilities 16,526 16,329
Commitments and contingencies
Stockholders’ equity:    
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.0001 par value: 100,000,000 shares authorized; 68,694,043 and 59,456,493 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively 7 6
Additional paid-in capital 803,718 693,534
Accumulated other comprehensive income (loss) 45 (58)
Accumulated deficit (546,139) (523,064)
Total stockholders’ equity 257,631 170,418
Total liabilities and stockholders’ equity $ 274,157 $ 186,747